

## **Supplemental Material**



### **Biglycan is a novel mineralocorticoid receptor target involved in aldosterone/salt-induced glomerular injury**

Toshifumi Nakamura<sup>1</sup>, Benjamin Bonnard<sup>1</sup>, Roberto Palacios-Ramirez<sup>1</sup>, Amaya Fernández-Celis<sup>2</sup>, Frédéric Jaisser<sup>1,3</sup>, and Natalia López-Andrés<sup>2</sup>.

<sup>1</sup> Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France.


<sup>2</sup> Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

<sup>3</sup> INSERM, Clinical Investigation Centre 1433, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

**A****B**


**Figure S1. NAS treatment-induced renal fibrosis is blunted by eplerenone.**

Representative microphotographs of mouse kidney sections with Sirius red observed by polarized light microscopy (A). Profibrotic gene mRNA levels (B). 20× (scale bar = 100 μm) and 40× (scale bar = 50 μm) magnification. One-way ANOVA was used for statistical analysis, n = 6–8. \*P < 0.05. NAS, uninephrectomy/aldosterone/salt; Eple, eplerenone; Col1a1, collagen type 1a1; Col3a1, collagen type 3a1; TGF-β1, transforming growth factor-β1.




**Figure S2. Eplerenone blunts the NAS-induced increase of biglycan expression in the kidney cortex.**

Representative immunoblots of biglycan and  $\beta$ -actin. The box plots show the individual data normalized to the level of  $\beta$ -actin. One-way ANOVA was used for statistical analysis,  $n = 6-8$ . \* $P < 0.05$ . NAS, uninephrectomy/aldosterone/salt; Eple, eplerenone.



**Figure S3. Dose-dependency of the biglycan effect on macrophages.**

Isolated peritoneal macrophages were treated with the indicated concentrations of biglycan (0.2–5.0  $\mu$ g/ml) for 4 h. One-way ANOVA was used for statistical analysis,  $n = 6–8$ . \* $P < 0.05$ . TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; iNOS, inducible nitric oxide synthase; Nox2, NADPH oxidase 2; CCL3, C-C motif chemokine ligand 3; BGN, biglycan.



**Figure S4. Proposed mechanism of biglycan-induced glomerular injury**

**Table S1. Primers used for gene expression analyses**

Gene product name		Primer Sequence
GAPDH	Forward	5'-AATGGTGAAGGTCGGTGTG-3'
	Reverse	5'-GAAGATGGTGATGGGCTTCC-3'
Collagen type 1a1	Forward	5'-GCTCCTCTTAGGGGCCACT-3'
	Reverse	5'-CCACGTCTCACCATTGGGG-3'
Collagen type 3a1	Forward	5'-CTGGAGCCCCTGGACTAATAG-3'
	Reverse	5'-GCCCATTTGCACCAGGTTCT-3'
TGF- $\beta$ 1	Forward	5'-TGCGCTTGCAGAGATTAAAA-3'
	Reverse	5'-CTGCCGTACAACCTCCAGTGA-3'
Lumican	Forward	5'-TCGAGCTTGATCTCTCCTAT -3'
	Reverse	5'-TGGTCCCAGGATCTTACAGAA-3'
Biglycan	Forward	5'-CTACGCCCTGGTCTTGGTAA-3'
	Reverse	5'-ACTTTGCGGATACGTTGTG-3'
Syndecan-1	Forward	5'-ACTTCACCTTTGAAACATCTGGG-3'
	Reverse	5'-CATCCGGTACAGCATGAAAGC-3'
Syndecan-4	Forward	5'-CATCTTTGAGAGAACTGAGGTCTTG-3'
	Reverse	5'-CCTTCTTCTTCATGCGGTACA-3'
CD68	Forward	5'-ACAAGGGACACTTCGGGCCA-3'
	Reverse	5'-GTCGTCTGCGGGTGATGCAG-3'
CD86	Forward	5'-AGCAGACGCGTAAGAGTGGCT-3'
	Reverse	5'-CATGGTGCATCTGGGGTCCATC-3'
CD206	Forward	5'-CCACAGCATTGAGGAGTTTG-3'
	Reverse	5'-ACAGCTCATCATTTGGCTCA-3'
CCL2	Forward	5'-GGCTGGAGAGCTACAAGAGG-3'
	Reverse	5'-TCTTGAGCTTGGTGACAAAAC-3'
CXCL2	Forward	5'-ATCCAGAGCTTGAGTGTGACGC-3'
	Reverse	5'-AAGGCAAACTTTTGACCGCC-3'
CCL5	Forward	5'-GCCCTCACCATCATCCTCACT-3'
	Reverse	5'-GGCGGTTCTTCGAGTGACA-3'
CXCL13	Forward	5'-ATATGTGTGAATCCTCGTGCCA-3'
	Reverse	5'-GGGAGTTGAAGACAGACTTTTGC-3'
CCL3	Forward	5'-TTCTCTGTACCATGACACTCTGC-3'
	Reverse	5'-CGTGGAATCTTCCGGCTGTAG-3'
TNF- $\alpha$	Forward	5'-CATCTTCTCAAAATTCGAGTGACAA-3'
	Reverse	5'-TGGGAGTAGACAAGGTACAACCC-3'
iNOS	Forward	5'-GCCAAGGCCAAACACAGCATAC-3'
	Reverse	5'-TGGCCACCTTGTTTCAGCTACG-3'
Nox2	Forward	5'-CGCCCTTTGCCTCCATTCTC-3'
	Reverse	5'-CCTTTCCTGCATCTGGGTCTCC-3'

GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TGF- $\beta$ 1, transforming growth factor  $\beta$ 1; CCL2, C-C motif chemokine ligand 2; CCL3, C-C motif chemokine ligand 3; CCL5, C-C motif chemokine ligand 5; CXCL2, C-X-C motif chemokine ligand 2; CXCL13, C-X-C motif chemokine ligand 13; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; iNOS, inducible nitric oxide synthase; Nox2, NADPH oxidase 2.